Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425782 | 0.86 | HRH1 (0.44) | HRH1LMNASCN1ASCN8ASMN1; SMN2 | |
| SCHEMBL12384560 | 0.86 | HRH1 (0.47) | HRH1LMNASCN1ASCN8AALDH1A1 | |
| SCHEMBL12384599 | 0.85 | HRH1 (0.43) | HRH1LMNASCN1ASCN8AALDH1A1 | |
| SCHEMBL12424314 | 0.71 | ACHE (0.47) | SCN1ASCN8AACHEHRH3DRD2 | |
| SCHEMBL15214330 | 0.71 | DRD2 (0.44) | HRH1LMNAALDH1A1ACHEHRH3 | |
| SCHEMBL31010156 | 0.70 | HRH1 (0.64) | HRH1LMNAALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL15014648 | 0.69 | TRPC3 (0.54) | LMNAALDH1A1ACHESMN1; SMN2 | |
| SCHEMBL9262966 | 0.69 | MCHR1 (0.34) | HRH1POLB | |
| SCHEMBL19083939 | 0.69 | TACR1 (0.45) | ACHEHRH3SMN1; SMN2DRD2DRD4 | |
| SCHEMBL12424287 | 0.68 | DDB1 (0.49) | ALDH1A1ACHEHRH3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HRH1 103/4885LMNA 1043/4885SCN1A 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.